Kymera Therapeutics Inc (KYMR) Operating Income 2018–TTM

Name: Kymera Therapeutics Inc (KYMR) operating income history 2018-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Kymera Therapeutics Inc annual operating income for fiscal TTM was -$351 million, a decrease of 0.6% from -$349 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

KYMR Annual Operating Income

Operating Income (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Operating Income (EBIT)	($351M)	($349M)	($262M)	($166M)	($161M)	($101M)	($46M)	($42M)	($21M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KYMR Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Operating Income (EBIT)	($76M)	($84M)	($98M)	($93M)	($85M)	($74M)	($81M)	($72M)	($51M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

CORT Operating Income — Corcept Therapeutics Incorporated
AXSM Operating Income — Axsome Therapeutics Inc
APGE Operating Income — Apogee Therapeutics, Inc. Common Stock
KRYS Operating Income — Krystal Biotech Inc
CYTK Operating Income — Cytokinetics Inc
ARWR Operating Income — Arrowhead Pharmaceuticals Inc

More KYMR metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All KYMR financial statements → Interactive KYMR charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.